Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing evaluation of Aprepitant
ChiCTR-OPN-17010567Phase 4Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: remission rate. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR-OPN-17010567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17010567.